Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
weight loss
Biotech
Aardvark halts obesity trials, putting entire pipeline on pause
The voluntary pause comes less than a month after Aardvark paused a phase 3 trial for a related asset due to cardiac concerns.
Darren Incorvaia
Mar 24, 2026 4:00am
Lilly triple-G bet sees 16.8% weight loss in ph. 3 diabetes test
Mar 19, 2026 6:45am
Structure touts 16% weight loss 'highest efficacy' for oral GLP1
Mar 16, 2026 10:02am
AbbVie ties $350M bet to almost 10% weight loss after 12 weeks
Mar 9, 2026 9:50am
Regeneron's obesity drug shows Zepbound-like efficacy in phase 3
Mar 9, 2026 8:25am
Zealand's Zupreme serves up to 10.7% mean weight loss
Mar 5, 2026 4:44pm